{
    "pmcid": "11374805",
    "qa_pairs": {
        "What RBD state in BA.2.86 is crucial for viral entry and should be targeted in vaccine strategies?": [
            "\"Partial-up\" state",
            "\"Full-down\" state",
            "\"Open\" state",
            "\"Closed\" state"
        ],
        "What mutation in the JN.1 variant significantly alters the interaction with the ACE2 receptor?": [
            "L455S mutation",
            "N501Y mutation",
            "D614G mutation",
            "E484K mutation"
        ],
        "What structural feature should nanobody designs consider due to its presence in BA.2.86 and JN.1?": [
            "Additional glycosylation sites such as Asn354",
            "Increased hydrophobic regions",
            "Enhanced electrostatic interactions",
            "Decreased RBD flexibility"
        ],
        "Which monoclonal antibodies retain neutralizing activity against both BA.2.86 and JN.1?": [
            "SA55 and S309",
            "REGN10933 and REGN10987",
            "Bamlanivimab and Etesevimab",
            "Casirivimab and Imdevimab"
        ],
        "Which variants' plasma showed a significant reduction in neutralization against JN.1?": [
            "BA.4 or BA.5",
            "BA.1 or BA.3",
            "Alpha or Delta",
            "Gamma or Mu"
        ]
    }
}